Synergistic anti-tumour effects of 13-cis retinoic acid and lovastatin in pancreatic neuroendocrine tumour (BON1) cells through enhanced EGFR inhibition
Svenja Nölting, Elke Tatjana Aristizabal Prada, Michael Lauseker, Julian Maurer, Gerald Spöttl, Burkhard Göke, Karel Pacak, Ashley Grossman

Introduction
In our previous studies we found that the combination of 13-cis retinoic acid (13cRA) and lovastatin significantly reduced tumour growth in a mouse phaeochromocytoma allograft model, with the lowest microvessel density in the combination-treated tumours (Nölting et al., Endocrinology, 2014 Jul). We have now investigated the effect of 13cRA plus lovastatin on neuroendocrine (BON1, H727) and non-endocrine tumour (HepG2, Huh7) cell viability and signalling pathways (EGFR, AKT, ERK, p70S6K) to elucidate the underlying mechanism of action.

Methods
Cell viability was assessed with the MTS assay, the effect on signalling pathways by Western blotting. For cell viability data, the multiple-comparison Kruskal-Wallis-Test was used, followed by pairwise comparisons with the Mann-Whitney-Test. Interaction effects were analysed with Linear-Mixed-Effects-Models. Statistical significance was defined as p≤0.05.

Results
Fig. 2

Fig. 2: The combination of 10μM lovastatin plus 7.5μM 13cRA shows synergistic inhibition of BON1 cell viability (p≤0.05) (@)

Conclusion
• Synergistic effect of 13cRA plus lovastatin in BON1 cells at clinically relevant doses, associated with enhanced EGFR inhibition
• Consistent with our in vivo data in a phaeochromocytoma allograft model showing slowest tumour growth and lowest microvessel density after 13cRA/lovastatin-treatment
• Potentially novel effective drug combination

Fig. 3

Fig. 3: In H727 cells, 10μM lovastatin plus 3.75μM or 7.5μM 13cRA significantly more strongly reduces cell viability than each drug separately (p≤0.05) (*), but this effect is not synergistic.

Fig. 4

Fig. 4: Exemplary western blots of each cell line tested: In BON1, HepG2 and Huh7 cells, combination-treatment (green) decreases pEGFR by more than 50% relative to each drug separately (yellow/blue), and by more than 80% relative to the untreated control. This effect is less pronounced in H727 cells.